Determinations of the DNA Sequence of the *mreB* Gene and of the Gene Products of the *mre* Region That Function in Formation of the Rod Shape of *Escherichia coli* Cells

MASAKI DOI,¹† MASAAKI WACHI,¹ FUMITOSHI ISHINO,¹ SHIGEO TOMIOKA,¹ MICHIHIKO ITO,¹ YOUJI SAKAGAMI,²‡ AKINORI SUZUKI,² and MICHIO MATSUHASHI¹*

Institute of Applied Microbiology¹ and Department of Agricultural Chemistry,² University of Tokyo, Bunkyo-ku, Tokyo, Japan

Received 25 April 1988/Accepted 29 June 1988

The 6.5-kilobase *mre* region at 71 min in the *Escherichia coli* chromosome map, where genes involved in formation of a rod-shaped cell form a gene cluster, was analyzed by in vivo protein synthesis in a maxicell system and by base sequencing of DNA. An open reading frame that may code for a protein with an M_r of about 37,000 on sodium dodecyl sulfate-polyacrylamide gels was found and was correlated with the *mreB* gene. N-terminal amino acid sequencing of the hybrid *mreB-lacZ* protein confirmed the production by *mreB* of a protein of 347 amino acid residues with a molecular weight of 36,958. The amino acid sequence of this protein deduced from the DNA sequence showed close similarity with that of a protein of the *ftsA* gene which is involved in cell division of *E. coli*. Three other contiguous genes that formed three proteins with M_r s of about 40,000, 22,000, and 51,000, respectively, were detected downstream of the *mreB* gene by in vivo protein synthesis. The *mreB* protein and some of these three proteins may function together in determination of cell shape.

Two regions called mrd (15) and mre (11) on the Escherichia coli chromosome involve clusters of genes responsible for determination of the cell shape and the sensitivity of cell growth to an amidinopenicillin, mecillinam. The mrd region located at 15 min on the E. coli chromosome map involves two genes for formation of the rod shape of the cell, mrdA (= pbpA), which codes for penicillin-binding protein 2, a peptidoglycan synthetase, and mrdB (= rodA), which codes for the RodA protein which may also be necessary for functioning of the mrdA protein (5). The mre region located at 71 min on the chromosome map involves genes that probably function together in shape determination and mecillinam sensitivity of the cell (17). Previously, we reported preliminary results of gene analysis of the apparent 7-kilobase (kb) mre region neighboring the fabE gene (17). The gene we called mreB (11), which may be allelic to envB (18) and in which the mutation mre-129 causing a round cell and supersensitivity to mecillinam is located, was cloned in a 2.8-kb DNA fragment. However, we found that another mutation, mre-678, causing a round cell, resistance to mecillinam, and overproduction of penicillin-binding proteins 1Bs and 3 was due to deletion of a 5.2-kb DNA fragment extending from the mreB gene and could not be complemented by the 2.8-kb fragment (17).

The present report describes the in vivo identification of the protein products of the genes located in the *mre* region (the size of the *Sal*I fragment is corrected to 6.5 kb from that in the previous report) by using a maxicell system (13) and DNA sequencing of a 2.1-kb *HincII* region involving the *mreB* gene.

MATERIALS AND METHODS

Bacterial strains. E. coli K-12 strain CSR603 (uvrA6 recA1 phr-1 thr leu pro his thi arg lac gal ara xyl mtl rpsL) used for protein synthesis in the maxicell system was obtained from B. J. Bachmann, Yale University School of Medicine. Strain JM109 (Δlac -proAB recA1 endA1 gyrA96 thi hsdR17 supE44 relA1 λ^{-} F' traD36 proAB lacI⁴ $\Delta lacZM15$) used for DNA sequencing experiments was obtained from Takara Shuzo Co., Kyoto, Japan.

Culture media. Modified Lennox broth (9) supplemented with 20 mg of thymine per liter and 50 μ g of lipoic acid per liter, called L'lip-broth (15), was used for growing cells unless otherwise indicated. For growing cells carrying plasmids, 25 mg of kanamycin, 25 mg of chloramphenicol, and 50 mg of aminobenzylpenicillin per liter were added to the broth.

[³⁵S]methionine labeling of proteins in the maxicell system. The maxicell system was used for labeling proteins with [³⁵S]methionine in in vivo synthesis of proteins coded by genes on plasmids (13). In a typical experiment, exponentially growing cells (2 \times 10⁸ cells per ml) in 7 ml of M9 medium plus 1% Casamino Acids (Difco Laboratories, Detroit, Mich.) were UV irradiated and then incubated at 30°C for 1 h with shaking. Then D-cycloserine (200 mg/liter) was added, and incubation was continued for 12 h. The cells were collected and washed twice with modified Hershey medium (19). They were then suspended in 1 ml of modified Hershey medium and incubated at 37°C for 1 h. Then [35S]methionine (6.3 μ Ci) was added, and the reaction was carried out at 37°C for 1 h. The labeled proteins were separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (8), and radioactivity was detected by fluorography.

DNA sequencing. The dideoxynucleotide method (14) with the Klenow fragment of E. *coli* DNA polymerase I was applied directly to the denatured double-stranded DNA

^{*} Corresponding author.

[†] Present address: Yamanouchi Pharmaceutical Co. Ltd., Itabashi-ku, Tokyo, 174 Japan.

[‡] Present address: Department of Agricultural Chemistry, Nagoya University, Chigusa-ku, Nagoya, 464 Japan.



FIG. 1. Proteins encoded by plasmids in the maxicell system. Two gels, a 10% acrylamide gel (A) and a 12.5% acrylamide gel (B), were used. Numbers indicate molecular weight. The DNA fragments used for in vivo protein synthesis and a summary of the results (solid lines at the bottom indicating approximate location of the open reading frames) are shown in panel C. Abbreviations: Ap, β -lactamase; Km, kanamycin phosphotransferase; Cm, chloramphenicol acetyltransferase; Ba, *Bam*H1; C. *Cla*1; E. *Eco*RV; H. *Hinc*I1; K. *Kpn*1; P. *Pst*1; S, *Sal*1; Sp, *Sph*1.

plasmid pUC19 (3) carrying fragments of the *E. coli* chromosome.

Plasmid construction. Plasmid pMC1403 (1), used for construction of the *mreB-lacZ* fusion gene, was obtained from H. Matsuzawa, University of Tokyo. The isolations of low-copy plasmids pMEL1, pMEL1K, pMEL3, and pMEL4 have been reported (17). Plasmids pMEY15, pMEY16, and pMEY17 were constructed by ligation of high-copy plasmid pACYC184 with fragments of pMEL1 obtained by digestion with appropriate restriction endonucleases. Plasmids pME U2, pMEU3, pMEU15, and pMEU27 were constructed by ligation of appropriate endonuclease-digested DNA fragments of pMEL1 with high-copy plasmid pUC19.

Construction of mreB-lacZ fusion gene and N-terminal amino acid sequencing of fusion protein. The 1.1-kb HincII-EcoRV fragment (nucleotides 4 to 1107 in Fig. 2) of pMEL3 was inserted into the SmaI site of pMC1403, which could make an in-frame joint between the N-terminal part of mreB and the C-terminal part of lacZ. Strain JM109 carrying the constructed plasmid pEHB3 was grown in L'lip-broth, and the fusion protein was overproduced after amplification of the plasmid by treatment with 170 mg of chloramphenicol per liter. The cells were disrupted in a French press (16,000 lb/in²), and the membrane fraction, in which the major part of the β -galactosidase activity was recovered, was collected by ultracentrifugation (100,000 \times g) and subjected to SDSpolyacrylamide gel electrophoresis (7.5% gel). The band corresponding to an M_r of 150,000, which is the expected size of the mreB-lacZ fusion protein, was cut out from the gel. The protein was eluted and concentrated in a Max-Yield-GP protein concentrator (AE-3590; ATTO Co. Ltd., Tokyo, Japan) in N-ethylmorpholine acetate buffer (pH 8.5) containing 0.1% SDS. The protein was precipitated with acetone and introduced into a gas-phase amino acid sequencer (ABI 470A; Applied Biosystems, Inc., Foster City, Calif.).

Radioactive materials and reagents. [35 S]methionine (1,470 Ci/mmol) and [α - 32 P]dCTP (410 Ci/mmol) were purchased from Amersham International plc, Amersham, Buckinghamshire, England. SDS and D-cycloserine were purchased from

Sigma Chemical Co., St., Louis, Mo. Other reagents and enzymes for DNA recombination experiments were also commercial products.

RESULTS

Identification of gene products in mre region in the maxicell system. The clone of the 6.5-kb chromosomal DNA fragment containing the mre region (17) was separated into subclones for identification of gene products (Fig. 1). The proteins formed by genes located on the 6.5-kb DNA fragment were detected in the maxicell system. The SDS-polyacrylamide gel electrophoresis patterns of proteins labeled by [³⁵S] methionine are shown in Fig. 1A (10% acrylamide gel for higher-molecular-weight protein) and Fig. 1B (12.5% acrylamide gel for lower-molecular-weight protein). These plasmids formed proteins that could be attributed to the expression of the genes located on chromosomal fragments in the plasmids in addition to products of the drug resistance genes on the vector plasmids. The low-copy-number plasmid pMEL1, which contained the whole 6.5-kb fragment, formed three higher-molecular-weight proteins with M_r s of about 51,000, 40,000, and 37,000 on the 10% gel (Fig. 1A). A plasmid with a deletion of 4 base pairs at the unique KpnI site, pMEL1K, which could not complement either the mre-129 or mre-678 mutation (17) did not form the 37kilodalton (kDa) protein. These results established that the 37-kDa protein is formed from the mreB gene that contains the unique KpnI site. This protein was also formed from the low-copy-number plasmids pMEL3 and pMEL4, which both contained a 2.8-kb ClaI-SalI fragment, but was not formed from the high-copy-number plasmids pMEY15, pMEY16, and pMEY17, which did not have the entire fragment (Fig. 1A).

The two other proteins of 51 and 40 kDa were formed from pMEL1K. The 51-kDa protein was also formed from the high-copy-number plasmid pMEY15 containing the 1.8-kb *SphI* fragment, but not from pMEY16, which did not contain the complete *SphI* fragment (Fig. 1A). These results suggest that this protein was coded by the gene located on the 1.8-kb



B

HincII TCAACCAGGCTGGTTTGACGCTGGTAAGTACCAGTTGGATCAAAGAACTTAATGTGAGTTACTCAAGCTCCATCCGGGGCTGGTCAGA V N Q A G L T L V S T S W 1 K E L N V F L L K L H P G L V R $\begin{array}{ccccccc} 100 & {\sf PvuII}. \\ {\sf Aacattagaaaccaaccagaaccagcaaccagctoctagttcaaagcctggtgaagcctgctccaggaaccagcaccaggtttacgccaccggc \\ {\sf N} & 1 & {\sf E} & {\sf K} & {\sf R} & {\sf T} & {\sf E} & {\sf N} & {\sf Q} & {\sf L} & {\sf V} & {\sf V} & {\sf E} & {\sf A} & {\sf C} & {\sf S} & {\sf G} & {\sf T} & {\sf S} & {\sf T} & {\sf V} & {\sf Y} & {\sf A} & {\sf T} & {\sf G} \\ \end{array}$ NAFI 200 GTGCGTTCGCGAAGCGAGTGGCAGACCCTGATTCAGCGCGGGGGCAAGGGGGATTTTTTCGCGTCCTCACAGCCACTTGAT V R S R S E W Q T L I Q R G V T G G Q G D F F A S S Q P L D 300 Actaacgtgaaaaaaatattcacaaagatactcggtttaacctgccgtttaatccgtttaatccgtagaataatgcgcgctgcgtcccatgg t N V K K V S Q R V S V S AVALILI 500 CCATTAAGCCTTTCTGGACTCAGGCAGAGATTTGTAACAAAGGAAACGAACTGCACTAATTTTCACCGTAGCAGATGATTTTTGCGCC<u>TT</u> 700 GGCATGTTTTCCCAATGACTGGCTACTGGGTACTGCGAATACCCTCATTTATGTAAAGGACAAGGCATCGTATTGAATGAGCC G M F S N D L S I D L G T A N T L I Y V K G Q G I V L N E P CCGGGCAATATTGCTGCCATTGAAGAAGACGGCGTTATCGCCGACTTCTTCGTGACTGAAAAAATGCTCCAGCACTTCATCATCA CAAGTGCAACAGCAACAGCTTTATGCGTCCAAGCCCGCGGTCTGGGCGGGGACCCAGGTTGAACGCCGCGGAATT Q V H S N S F M R P S P R V L V C V P V G A T Q V E R R A T 1000 CGTGAATCCGCGCAGGGCGCTGGTGCCCGTGAAGTCTTCCTGATTGAAGAACCGATGGCTGCCGCAATTGGTGCTGGCCTGCCGGTTTCT R R S A Q G A G A R E V F L I F E P M A A A I G A G L P V S 1100 ECORV. KpnI GAAGCGACCGGTTCTATGGTGGTGTGATTCCGCTGGTGGGTTTACTCCTCTTCT E A T G S M V V D I G G G T T E V A V I S I. N G V V Y S S S $\begin{array}{c} 1200\\ \texttt{GTGCGCATTGGTGGTGACCGTTTCGACGAAGCTATCATCATCATGTGCGTCGTAATTACGGTTCTCTGATCGGTGAAGCCACCGCAGAA\\ V~R~I~G~G~D~R~F~D~E~A~I~I~N~V~V~R~N~V~G~S~L~I~G~E~A~T~A~E\\ \end{array}$. Pall 1400 processes to the construction of 1600 LCO47III TTGCCGACAGCCGCCTGGGGACGTTCAGTCAAATCCGTACTTATTGGATACCGCCGTCAGTCCTTTCTACTTTGTTTCCAATGCTCCTC I A D S R I G T F S Q I R T Y M D T A V S P F Y F V S N A P 1900 GTGAATTGCTGGGTGGGCTGGCGTGGCCTGGCGTGGCCGTGACGACTGGAAACCGGGGGGTTACGTCAGGAACTGTTGCTGA \mathbf{K} \mathbf{F} \mathbf{L} \mathbf{L} \mathbf{D} \mathbf{G} \mathbf{V} \mathbf{S} \mathbf{Q} \mathbf{T} \mathbf{L} \mathbf{A} \mathbf{S} \mathbf{R} \mathbf{D} \mathbf{Q} \mathbf{L} \mathbf{E} \mathbf{L} \mathbf{E} \mathbf{N} \mathbf{R} \mathbf{A} \mathbf{L} \mathbf{R} \mathbf{Q} \mathbf{E} \mathbf{L} \mathbf{L}

Hincli AGAAAATGGTGACTCAGGTTATCTCCACGGTTAAC Q K M V T Q V I S T V N

FIG. 2. Strategy and result of DNA sequencing (A) and deduced amino acid sequence (B). The possible promoter and Shine-Dalgarno (SD) sequences are underlined. The termination codon is shown by an asterisk. Arrows indicate a palindrome sequence. Abbreviations for restriction endonucleases are as described in the legend to Fig. 1; in addition, Pv, PvuII; N, NruI; A, AvaIII; E4, Eco47III; R, RsaI.

mreB	MLKKFRGMFSNDLS I	15
ftsA	MIKATDRKLVVGLEIGTAKVAALVGEVLPDGMVNIIGVGSCPSRGMDKGGVNDLESVVKC	60
mreB	eq:dlgtantllyvkgqgivlnepsvvairqdragspksvaavghdanem lgrtpgniaairpdiaair	75
ftsA	$v\ QRAIDQAELMADCQISSVYLALSGKHISCQNEIGMVPISEEEVTQEDVENVVHTAKSVR$	120
mreB	${\tt MKDGVIASFFVTEKMLQHFIKQVHSNSFMRPSPRVLVCVPVGATQVERRAIRESAQGAGA}$	135
ftsA	VRDEHRVLHVIPQEYAIDYQEGIKNPVGLSGVRMQAKVHLITCHNDMAKNIVKAVERCGL	180
mreB	REVFLIEEPMAAAIGAGCRFLKATGSMVVDIGGGTTEVAVISLNGVVYSSSVRIGGDRFD	195
ftsA	KVDQLIFAGLASSYSVLTEDERELGVCVVDIGGGTMDIAVYTGGALRHTKVIPYAGNVVT	240
mreB	EAIINYVRRNYGSLIGEATAERIKHEIGSAYPGDEVREIEVRGRNLAEGVPRGFTLNS-N	254
ftsA	SD-IAYAFGTPPSDAEAIKVRHGCALGSIVGKDESVEVPSVGGRPPRSLQRQTLA	294
mreB	EILEALQEPLIGIVSAVMVALEHT-PPELASDISERGMVLTGGGALLRNLDRLLMEETGI	313
ftsA	*::*: : *:::*:: :::*:: ::: ::: : : : :	354
mreB	PVVVAEDPLTCVARGGGKALEMIDMHGGDLFSEE 347	
ftsA	QVRIGAPLNITGLTDYAQEPYYSTAVGLLHYGKESHLNGEAEVEKRVTASVGSWIKRLNS	414
ftsA	WLRKEF 420	

FIG. 3. Optimized alignment of mreB and ftsA proteins. The single-letter notation of amino acids is used. Identical residues are marked with an asterisk, and conservative replacements are shown by two dots. Insertions made during optimization are marked with a dash. The alignment is according to the program of Lipman and Person (10). Residue 338 of the FtsA protein given as A could be uncertain.

SphI fragment. The 40-kDa protein was formed from pMEL1 or pMEL1K, but not from any of the subclones in the high-copy-number plasmid in Fig. 1C. Thus, the gene coding for this protein may encompass either the 0.9-kb BamHI-ClaI region or a part of the terminal 0.4-kb SalI-SphI region of the total 6.5-kb SalI fragment. However, we think the latter possibility is less likely.

Formation of the 22-kDa protein by the high-copy-number plasmids pMEU3 and pMEU27, which both involve the 1.5-kb *PstI* fragment, could be detected in the 12.5% gel (Fig. 1B). Thus, the gene coding for the 22-kDa protein may be located between the genes coding for the 51- and 40-kDa proteins.

Determination of base sequence of *mreB* gene and Nterminal peptide sequence of *mreB* protein. The 2.1-kb *HincII* fragment, which could complement the *mre-129* mutation and involved the unique KpnI site, was obtained from plasmid pMEL1 for sequencing the *mreB* gene. The strategy and result of DNA sequencing of the 2.1-kb *HincII* fragment containing the *mreB* gene are shown in Fig. 2. A large open reading frame encompassing the *KpnI* site was detected as the sole candidate for the *mreB* gene. Three start codons were seen at GTG (544 to 546), GTG (553 to 555), and ATG (613 to 615). A termination codon for this frame was found at TAA (1654 to 1656).

To determine the N-terminal amino acid sequence of the *mreB* protein, we prepared a hybrid peptide of the N-terminal portion of the *mreB* protein and the C-terminal portion of the *lacZ* protein of *E. coli* as described in Materials and Methods. The N-terminal amino acid sequence NH_2 -MLKKFRXMFXND- was obtained, consistent with that deduced from the base sequence starting at the start codon ATG (613 to 615).

From these results, the protein formed from *mreB* should have 347 amino acid residues with a molecular weight of 36,958. Provided the start codon is at ATG (613 to 615),

candidates for promoter sequences may be TTGTCG (539 to 544, the -35 region) and TAAAGT (561 to 566, the -10 region). The possible Shine-Dalgarno sequence may be TCAGGA (595 to 600). The amino acid sequence upstream of the N-terminal methionine residue deduced from the DNA sequence, M (or MLRV) VGKVSGFSFPPQLSGLSLS, resembles a signal peptide sequence. If this sequence actually functions as a signal peptide, the starting codon would be GTG (544 to 546) or GTG (553 to 555). However, no promoterlike and Shine-Dalgarno-like sequences could be found in the close upstream region of these two GTG codons.

A palindrome sequence (1664 to 1695) that could construct an 11-base-pair stem and an 8-base loop was found shortly after the termination codon TAA (1654 to 1656). This sequence may function as a terminator, but this possibility requires further study.

The *mreB* gene is preceded by an apparent open reading frame on the same strand (1 to 306) continuing upstream of the *HincII* site, its possible protein product not having been detected. The termination codon of the unknown gene and the start codon ATG of the *mreB* protein are separated by a spacing sequence of 303 nucleotides. With a 65-base-pair spacing sequence downstream of the termination codon TAA of the *mreB* gene, a possible open reading frame on the same strand followed only the 384-base N-terminal sequence which is shown in Fig. 2. This probably codes for a 40-kDa protein. No reasonable promoterlike sequence could be found in this spacing region.

The hydropathy profile of the *mreB* protein sequence deduced from the base sequence was moderate (not shown). The codon usage indicated that this protein is formed in a large amount in the cells (4).

The homology of the base sequence of the *mreB* gene was surveyed in an EMBL gene library. Some homology was found with ftsA (12), which is a gene involved in cell

division. The homology of the protein products of the two genes was still higher. The C-terminal half of the *mreB* protein showed 24.5% amino acid identity in a 143-aminoacid overlap with a similar portion of the *ftsA* product (Fig. 3). The highest homologies were seen in two regions, eight consecutive amino acid residues from Val-163 through Thr-170 and five consecutive amino acid residues from Val-292 through Gly-296 of the *mreB* protein. The unique *Kpn*I site of the *mreB* gene was located in the homologous octapeptide region. Considering conservative replacement, the homology in the sequence of 143 amino acids was 71.3%.

DISCUSSION

The alignment of genes in the mre region is shown in Fig. 1C. The mreB gene coding for the 37-kDa protein was located close to the fabE gene. Based on the restriction map of the total E. coli chromosome (7), the mreB gene is transcribed counterclockwise, in the opposite direction of the fabE gene. Downstream of mreB, three genes were found that could code for a 40-kDa protein, a 22-kDa protein, and a 51-kDa protein in this order. The mre-129 mutation was located in the mreB gene, but the mre-678 mutation possessed a large deletion of the 5.2-kb DNA fragment extending over mreB and three other genes coding for the 22-, 40-, and 51-kDa proteins. The phenotyic changes caused by the mre-678 mutation could only be recovered by plasmids which carried this chromosomal area, such as pMEL1, but not by those that carried only a part of this area, such as pMEL3 or pMEL4 (17). The mreB protein and at least one of the three other proteins are definitely involved in the formation of the rod shape, mecillinam sensitivity, and the regulation of formation of penicillin-binding proteins 1Bs and 3 of the E. coli cell.

The strong homology of the C-terminal half of the *mreB* gene product with the *ftsA* protein suggests some relationship between the functions of these two proteins. The *ftsA* protein is involved in a late step of cell division (2), and the *mreB* protein is involved in formation of the rod shape of the cell. These proteins might function similarly. They possibly antagonize each other.

Previously, a report from this laboratory (16) indicated the presence of a gene named *mreA* that may be responsible for regulation of the penicillin-binding proteins 1A and 2 and its mutation, which was recessive to the wild type. The position of the *mreA* mutation was mapped roughly by use of a lambda transducing bacteriophage close to *mreB* (11; S. Nakajima-Iijima, Ph.D. thesis, University of Tokyo, Tokyo, Japan, 1981). The exact location of this gene and identification of the functional gene product require further investigation.

Several Rod⁻ mutations, named rodY (6) or envB (18), have been mapped close to this region. The fact that the envB mutation could be complemented by the plasmid pMEL4 (17) suggests that the envB gene could be identical to the *mreB* gene.

The mechanisms by which the *mreB* product and some other putative *mre* gene products function in formation of rod-shaped cells, induction of normal mecillinam sensitivity, and regulation of penicillin-binding proteins 1Bs and 3 need further investigation.

ACKNOWLEDGMENTS

We thank Hideo Sumiyoshi, Tokyo Metropolitan Institute of Medical Science, for helpful advice in determining the DNA sequence by using a double-stranded plasmid.

This work was partially supported by a Grant-in-Aid for Encouragement of Young Scientists (62790243 to M.W.) and a Grant-in-Aid for Scientific Research (61470157 to M.M.) from the Ministry of Education, Science and Culture of Japan. Masaaki Wachi is a fellow of the Japan Society for Promotion of Science for Japanese Junior Scientists.

LITERATURE CITED

- Casadaban, M. J., J. Chou, and S. N. Cohen. 1980. In vitro gene fusions that join an enzymatically active β-galactosidase segment to amino-terminal fragments of exogenous proteins: *Escherichia coli* plasmid vectors for the detection and cloning of translational initiation signals. J. Bacteriol. 143:971–980.
- Donachie, W. D., K. J. Begg, J. F. Lutkenhaus, G. P. C. Salmond, E. Martinez-Salas, and M. Vincente. 1979. Role of the *ftsA* gene product in control of *Escherichia coli* cell division. J. Bacteriol. 140:388–394.
- 3. Hattori, M., and Y. Sakaki. 1986. Dideoxy sequencing method using denatured plasmid templates. Anal. Biochem. 152:232-238.
- 4. Ikemura, T. 1981. Correlation between the abundance of *Escherichia coli* transfer RNAs and the occurrence of the respective codons in its protein genes: a proposal for a synonymous codon choice that is optimal for the *E. coli* translational system. J. Mol. Biol. 151:389–409.
- Ishino, F., W. Park, S. Tomioka, S. Tamaki, I. Takase, K. Kunugita, H. Matsuzawa, S. Asoh, T. Ohta, B. G. Spratt, and M. Matsuhashi. 1986. Peptidoglycan synthetic activities in membranes of *Escherichia coli* caused by overproduction of penicillin-binding protein 2 and RodA protein. J. Biol. Chem. 261: 7024–7031.
- Iwaya, M., C. W. Jones, J. Khorana, and J. L. Strominger. 1978. Mapping of the mecillinam-resistant, round morphological mutants of *Escherichia coli*. J. Bacteriol. 133:196–202.
- Kohara, Y., K. Akiyama, and K. Isono. 1987. The physical map of the whole *E. coli* chromosome: application of a new strategy for rapid analysis and sorting of a large genomic library. Cell 50: 495-508.
- Laemmli, U. K., and M. Favre. 1973. Maturation of the head of bacteriophage T4. I. DNA packaging events. J. Mol. Biol. 80: 575-599.
- 9. Lennox, E. S. 1955. Transduction of linked genetic characters of the host by bacteriophage P1. Virology 1:190–206.
- Lipman, D. J., and W. R. Person. 1985. Rapid and sensitive protein similarity searches. Science 227:1435–1441.
- 11. Matsuhashi, M., F. Ishino, S. Tamaki, S. Nakajima-Iijima, S. Tomioka, J. Nakagawa, A. Hirata, B. G. Spratt, T. Tsuruoka, S. Inouye, and Y. Yamada. 1982. Mechanism of action of β -lactam antibiotics: inhibition of peptidoglycan transpeptidases and novel mechanisms of action, p. 99–114. *In* H. Umezawa, A. L. Demain, T. Hata, and C. R. Hutchinson (ed.), Trends in antibiotic research. Japan Antibiotics Research Association, Tokyo, Japan.
- Robinson, A. C., D. J. Kenan, G. F. Hatfull, N. F. Sullivan, R. Spiegelberg, and W. D. Donachie. 1984. DNA sequence and transcriptional organization of essential cell division genes *ftsQ* and *ftsA* of *Escherichia coli*: evidence for overlapping transcriptional units. J. Bacteriol. 160:546-555.
- Sancar, A., A. M. Hack, and W. D. Rupp. 1979. Simple method for identification of plasmid-coded proteins. J. Bacteriol. 137: 692-693.
- Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463-5467.
- Tamaki, S., H. Matsuzawa, and M. Matsuhashi. 1980. Cluster of mrdA and mrdB genes responsible for the rod shape and mecillinam sensitivity of *Escherichia coli*. J. Bacteriol. 141:52–

57.

- Tamaki, S., S. Nakajima, and M. Matsuhashi. 1977. Thermosensitive mutation in *Escherichia coli* simultaneously causing defects in penicillin-binding protein-1Bs and in enzyme activity for peptidoglycan synthesis *in vitro*. Proc. Natl. Acad. Sci. USA 74: 5472-5476.
- 17. Wachi, M., M. Doi, S. Tamaki, W. Park, S. Nakajima-Iijima, and M. Matsuhashi. 1987. Mutant isolation and molecular cloning of *mre* genes, which determine cell shape, sensitivity to

mecillinam, and amount of penicillin-binding proteins in Escherichia coli. J. Bacteriol. 169:4935-4940.

- Westling-Häggström, B., and S. Normark. 1975. Genetic and physiological analysis of an *envB* spherelike mutant of *Escherichia coli* K-12 and characterization of its transductants. J. Bacteriol. 123:75–82
- Worcel, A., and E. Burgi. 1974. Properties of a membraneattached form of the folded chromosome of *Escherichia coli*. J. Mol. Biol. 82:91–105.